Symbols / DARE Stock $2.10 -4.11% Daré Bioscience, Inc.

Healthcare • Biotechnology • United States • NCM
DARE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Ms. Sabrina Martucci Johnson
Exch · Country NCM · United States
Market Cap 30.57M
Enterprise Value 8.52M
Income -13.40M
Sales 1.03M
FCF (ttm) -4.80M
Book/sh 0.20
Cash/sh 1.70
Employees 21
Insider 10d —
IPO Apr 10, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 3.59
PEG —
P/S 29.68
P/B 10.71
P/C —
EV/EBITDA -0.71
EV/Sales 8.27
Quick Ratio 1.07
Current Ratio 1.14
Debt/Eq 93.44
LT Debt/Eq —
EPS (ttm) -1.20
EPS next Y 0.58
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2026-03-26
ROA -31.04%
ROE —
ROIC —
Gross Margin 71.29%
Oper. Margin -143.72%
Profit Margin 0.00%
Shs Outstand 14.56M
Shs Float 13.31M
Insider Own 8.32%
Instit Own 8.44%
Short Float 1.18%
Short Ratio 1.64
Short Interest 170.17K
52W High 9.19
vs 52W High -77.15%
52W Low 1.27
vs 52W Low 65.35%
Beta 0.90
Impl. Vol. —
Rel Volume 0.60
Avg Volume 360.12K
Volume 215.05K
Target (mean) $9.67
Tgt Median $9.00
Tgt Low $8.00
Tgt High $12.00
# Analysts 3
Recom None
Prev Close $2.19
Price $2.10
Change -4.11%
About

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.67
Mean price target
2. Current target
$2.10
Latest analyst target
3. DCF / Fair value
$-5.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.10
Low
$8.00
High
$12.00
Mean
$9.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-02 reit HC Wainwright & Co. Buy → Buy $12
2025-09-04 up Maxim Group Hold → Buy $8
2025-04-01 reit HC Wainwright & Co. Buy → Buy $12
2024-12-17 reit HC Wainwright & Co. Buy → Buy $12
2024-11-15 reit HC Wainwright & Co. Buy → Buy $12
2024-10-24 reit HC Wainwright & Co. Buy → Buy $12
2024-08-16 main Jones Trading Buy → Buy $13
2024-08-14 down Maxim Group Buy → Hold —
2024-05-15 reit HC Wainwright & Co. Buy → Buy $6
2024-05-15 up Brookline Capital Hold → Buy $3
2024-05-01 reit HC Wainwright & Co. Buy → Buy $6
2024-04-17 down Brookline Capital Buy → Hold —
2024-04-01 reit HC Wainwright & Co. Buy → Buy $6
2023-11-10 main HC Wainwright & Co. Buy → Buy $6
2023-08-11 reit HC Wainwright & Co. Buy → Buy $7
2023-07-13 reit HC Wainwright & Co. Buy → Buy $7
2023-06-06 reit HC Wainwright & Co. — → Buy $7
2023-05-22 reit HC Wainwright & Co. Buy → Buy $7
2023-05-12 reit HC Wainwright & Co. Buy → Buy $7
2023-03-31 reit HC Wainwright & Co. — → Buy $7
News
RSS: Latest DARE news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.03
+10429.36%
0.01
-99.65%
2.81
-71.92%
10.00
Operating Revenue
1.03
+10429.36%
0.01
-99.65%
2.81
-71.92%
10.00
Cost Of Revenue
0.30
—
—
—
Reconciled Cost Of Revenue
0.30
—
—
—
Gross Profit
0.73
—
—
—
Operating Expense
14.29
-39.11%
23.46
-30.48%
33.75
-18.46%
41.39
Research And Development
5.52
-61.39%
14.31
-33.58%
21.54
-28.31%
30.04
Selling General And Administration
8.76
-4.29%
9.16
-24.39%
12.11
+7.71%
11.24
General And Administrative Expense
8.76
-4.29%
9.16
-24.39%
12.11
+7.71%
11.24
Other Gand A
8.76
-4.29%
9.16
-24.39%
12.11
+7.71%
11.24
Other Operating Expenses
—
0.10
+0.00%
0.10
+0.00%
0.10
Total Expenses
14.58
-37.84%
23.46
-30.48%
33.75
-18.46%
41.39
Operating Income
-13.55
+42.21%
-23.45
+24.20%
-30.94
+1.42%
-31.39
Total Operating Income As Reported
-13.55
+42.21%
-23.45
+24.20%
-30.94
+1.42%
-31.39
EBITDA
-11.92
+49.09%
-23.41
+24.25%
-30.90
+1.47%
-31.36
Normalized EBITDA
-11.92
+72.78%
-43.79
-41.70%
-30.90
+1.47%
-31.36
Reconciled Depreciation
1.63
+3761.75%
0.04
+10.33%
0.04
+58.51%
0.02
EBIT
-13.55
+42.21%
-23.45
+24.20%
-30.94
+1.42%
-31.39
Total Unusual Items
0.00
-100.00%
20.38
0.00
0.00
Total Unusual Items Excluding Goodwill
0.00
-100.00%
20.38
0.00
0.00
Special Income Charges
0.00
-100.00%
20.38
0.00
0.00
Other Special Charges
—
—
—
—
Net Income
-13.40
-230.55%
-4.05
+86.56%
-30.16
+2.54%
-30.95
Pretax Income
-13.40
-230.55%
-4.05
+86.56%
-30.16
+2.54%
-30.95
Other Income Expense
0.15
-99.21%
19.40
+2391.74%
0.78
+77.84%
0.44
Other Non Operating Income Expenses
0.15
+115.59%
-0.98
-226.08%
0.78
+77.84%
0.44
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-13.40
-230.55%
-4.05
+86.56%
-30.16
+2.54%
-30.95
Net Income From Continuing Operation Net Minority Interest
-13.40
-230.55%
-4.05
+86.56%
-30.16
+2.54%
-30.95
Net Income From Continuing And Discontinued Operation
-13.40
-230.55%
-4.05
+86.56%
-30.16
+2.54%
-30.95
Net Income Continuous Operations
-13.40
-230.55%
-4.05
+86.56%
-30.16
+2.54%
-30.95
Normalized Income
-13.40
+45.16%
-24.43
+18.99%
-30.16
+2.54%
-30.95
Net Income Common Stockholders
-13.40
-230.55%
-4.05
+86.56%
-30.16
+2.54%
-30.95
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
-1.20
-150.00%
-0.48
+88.43%
-4.15
+6.53%
-4.44
Basic EPS
-1.20
-150.00%
-0.48
+88.43%
-4.15
+6.53%
-4.44
Basic Average Shares
11.18
+31.55%
8.50
+16.80%
7.28
+3.23%
7.05
Diluted Average Shares
11.18
+31.55%
8.50
+16.80%
7.28
+3.23%
7.05
Diluted NI Availto Com Stockholders
-13.40
-230.55%
-4.05
+86.56%
-30.16
+2.54%
-30.95
Gain On Sale Of PPE
0.00
-100.00%
20.38
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
32.47
+46.94%
22.10
+3.85%
21.28
-51.44%
43.83
Current Assets
27.06
+46.70%
18.45
+5.15%
17.54
-59.24%
43.04
Cash Cash Equivalents And Short Term Investments
24.71
+57.42%
15.70
+49.85%
10.48
-69.78%
34.67
Cash And Cash Equivalents
24.71
+57.42%
15.70
+49.85%
10.48
-69.78%
34.67
Receivables
0.57
+149.18%
0.23
-75.77%
0.95
-44.27%
1.70
Other Receivables
0.57
+149.18%
0.23
-75.77%
0.95
-44.27%
1.70
Prepaid Assets
1.39
-44.74%
2.52
-58.82%
6.12
-8.22%
6.67
Current Deferred Assets
0.32
0.00
—
—
Other Current Assets
0.07
—
—
—
Total Non Current Assets
5.41
+48.11%
3.65
-2.28%
3.74
+374.67%
0.79
Net PPE
4.40
+73.10%
2.54
+28.70%
1.98
+277.87%
0.52
Gross PPE
4.74
+74.33%
2.72
+28.16%
2.12
+305.73%
0.52
Accumulated Depreciation
-0.34
-92.17%
-0.18
-20.72%
-0.15
—
Properties
0.00
0.00
0.00
—
Buildings And Improvements
—
1.21
-8.54%
1.32
—
Machinery Furniture Equipment
0.05
+28.70%
0.04
-28.36%
0.05
—
Construction In Progress
0.00
-100.00%
1.23
+104.86%
0.60
—
Other Properties
4.65
+229.42%
1.41
-1.07%
1.43
+172.96%
0.52
Leases
0.04
+0.00%
0.04
-4.51%
0.04
—
Non Current Deferred Assets
—
—
—
0.14
Non Current Prepaid Assets
—
0.01
-98.97%
1.16
+10978.62%
0.01
Other Non Current Assets
1.01
-9.11%
1.11
+85.22%
0.60
+135.79%
0.25
Total Liabilities Net Minority Interest
29.63
+5.40%
28.11
+6.77%
26.33
-19.52%
32.71
Current Liabilities
23.69
+9.59%
21.61
+5.53%
20.48
-35.24%
31.62
Payables And Accrued Expenses
1.92
-48.13%
3.69
-32.47%
5.47
-51.17%
11.20
Payables
1.38
-18.90%
1.71
-53.39%
3.66
+80.44%
2.03
Accounts Payable
1.20
-17.53%
1.46
-57.00%
3.39
+66.94%
2.03
Other Payable
0.18
-26.88%
0.25
-8.79%
0.27
—
Current Accrued Expenses
0.53
-73.21%
1.99
+9.82%
1.81
-80.27%
9.17
Pensionand Other Post Retirement Benefit Plans Current
0.01
-98.73%
0.81
+0.02%
0.81
-53.19%
1.72
Current Debt And Capital Lease Obligation
2.10
+282.16%
0.55
+17.05%
0.47
+17.65%
0.40
Current Capital Lease Obligation
2.10
+282.16%
0.55
+17.05%
0.47
+17.65%
0.40
Current Deferred Liabilities
19.65
+18.66%
16.56
+20.56%
13.74
-24.95%
18.30
Current Deferred Revenue
19.65
+18.66%
16.56
+20.56%
13.74
-24.95%
18.30
Other Current Liabilities
0.01
+188.88%
0.00
—
—
Total Non Current Liabilities Net Minority Interest
5.95
-8.52%
6.50
+11.12%
5.85
+436.47%
1.09
Long Term Debt And Capital Lease Obligation
0.56
-25.85%
0.75
-19.38%
0.94
+935.73%
0.09
Long Term Capital Lease Obligation
0.56
-25.85%
0.75
-19.38%
0.94
+935.73%
0.09
Non Current Deferred Liabilities
0.00
-100.00%
1.00
+0.00%
1.00
+0.00%
1.00
Non Current Deferred Revenue
0.00
-100.00%
1.00
+0.00%
1.00
+0.00%
1.00
Other Non Current Liabilities
5.39
+13.51%
4.75
+21.26%
3.91
—
Stockholders Equity
2.84
+147.28%
-6.01
-19.11%
-5.05
-145.42%
11.11
Common Stock Equity
2.84
+147.28%
-6.01
-19.11%
-5.05
-145.42%
11.11
Capital Stock
0.00
+66.67%
0.00
+4.44%
0.00
-90.18%
0.01
Common Stock
0.00
+66.67%
0.00
+4.44%
0.00
-90.18%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
14.50
+66.65%
8.70
+4.43%
8.33
+17.86%
7.07
Ordinary Shares Number
14.50
+66.65%
8.70
+4.43%
8.33
+17.86%
7.07
Additional Paid In Capital
191.95
+13.11%
169.71
+1.90%
166.55
+9.19%
152.53
Retained Earnings
-188.69
-7.64%
-175.29
-2.37%
-171.24
-21.38%
-141.07
Gains Losses Not Affecting Retained Earnings
-0.42
+1.68%
-0.43
-18.82%
-0.36
-2.73%
-0.35
Other Equity Adjustments
-0.42
+1.68%
-0.43
-18.82%
-0.36
-2.73%
-0.35
Total Equity Gross Minority Interest
2.84
+147.28%
-6.01
-19.11%
-5.05
-145.42%
11.11
Total Capitalization
2.84
+147.28%
-6.01
-19.11%
-5.05
-145.42%
11.11
Working Capital
3.38
+206.73%
-3.17
-7.77%
-2.94
-125.73%
11.41
Invested Capital
2.84
+147.28%
-6.01
-19.11%
-5.05
-145.42%
11.11
Total Debt
2.66
+103.84%
1.30
-7.22%
1.40
+187.37%
0.49
Capital Lease Obligations
2.66
+103.84%
1.30
-7.22%
1.40
+187.37%
0.49
Net Tangible Assets
2.84
+147.28%
-6.01
-19.11%
-5.05
-145.42%
11.11
Tangible Book Value
2.84
+147.28%
-6.01
-19.11%
-5.05
-145.42%
11.11
Current Notes Payable
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-9.89
-280.61%
5.47
+114.09%
-38.86
-114.81%
-18.09
Cash Flow From Continuing Operating Activities
-9.89
-280.61%
5.47
+114.09%
-38.86
-114.81%
-18.09
Net Income From Continuing Operations
-13.40
-230.55%
-4.05
+86.56%
-30.16
+2.54%
-30.95
Depreciation Amortization Depletion
1.63
+3761.75%
0.04
+10.33%
0.04
+58.51%
0.02
Depreciation
1.63
+3761.75%
0.04
+10.33%
0.04
+58.51%
0.02
Depreciation And Amortization
1.63
+3761.75%
0.04
+10.33%
0.04
+58.51%
0.02
Other Non Cash Items
-0.40
-150.82%
0.79
+194.14%
-0.84
-3531.16%
-0.02
Stock Based Compensation
1.50
-32.07%
2.20
-12.94%
2.53
+17.24%
2.16
Operating Gains Losses
-0.01
-101.05%
0.60
—
—
Gain Loss On Sale Of PPE
-0.01
-101.05%
0.60
0.00
—
Change In Working Capital
0.79
-86.61%
5.89
+156.52%
-10.43
-197.45%
10.70
Change In Receivables
-0.34
-147.70%
0.72
-4.60%
0.75
+235.15%
-0.56
Changes In Account Receivables
-0.01
0.00
—
—
Change In Prepaid Assets
0.67
-83.29%
4.00
+761.03%
-0.61
+85.55%
-4.19
Change In Payables And Accrued Expense
-1.93
-56.23%
-1.24
+82.10%
-6.91
-190.00%
7.68
Change In Accrued Expense
-1.68
-342.39%
0.69
+108.37%
-8.27
-206.63%
7.76
Change In Payable
-0.26
+86.78%
-1.93
-242.14%
1.36
+1906.95%
-0.08
Change In Account Payable
-0.26
+86.78%
-1.93
-242.14%
1.36
+1906.95%
-0.08
Change In Other Working Capital
3.09
+9.39%
2.82
+161.85%
-4.57
-158.84%
7.76
Change In Other Current Assets
-0.14
-416.33%
0.05
+542.35%
-0.01
-382.19%
0.00
Change In Other Current Liabilities
-0.55
-19.33%
-0.46
-150.21%
0.92
—
Investing Cash Flow
-0.39
+32.77%
-0.57
+8.96%
-0.63
-898.00%
-0.06
Cash Flow From Continuing Investing Activities
-0.39
+32.77%
-0.57
+8.96%
-0.63
-898.00%
-0.06
Net PPE Purchase And Sale
-0.39
+32.77%
-0.57
+8.96%
-0.63
-898.00%
-0.06
Purchase Of PPE
-0.39
+32.77%
-0.57
+8.96%
-0.63
-898.00%
-0.06
Capital Expenditure
-0.39
+32.77%
-0.57
+8.96%
-0.63
-898.00%
-0.06
Financing Cash Flow
19.28
+5337.50%
0.35
-97.73%
15.64
+1064.04%
1.34
Cash Flow From Continuing Financing Activities
19.28
+5337.50%
0.35
-97.73%
15.64
+1064.04%
1.34
Net Issuance Payments Of Debt
-1.33
-7481.41%
-0.02
-106.57%
0.27
0.00
Issuance Of Debt
0.49
-13.34%
0.56
-6.57%
0.60
0.00
Repayment Of Debt
-1.82
-213.87%
-0.58
-73.43%
-0.33
0.00
Long Term Debt Issuance
0.49
-13.34%
0.56
-6.57%
0.60
0.00
Long Term Debt Payments
-1.82
-213.87%
-0.58
-73.43%
-0.33
0.00
Net Long Term Debt Issuance
-1.33
-7481.41%
-0.02
-106.57%
0.27
0.00
Net Common Stock Issuance
20.93
+4514.44%
0.45
-95.15%
9.35
+666.91%
1.22
Proceeds From Stock Option Exercised
—
0.00
-100.00%
1.30
+942.80%
0.12
Net Other Financing Charges
-0.32
-294.72%
-0.08
-101.73%
4.72
—
Changes In Cash
9.01
+71.38%
5.26
+122.03%
-23.85
-41.89%
-16.81
Effect Of Exchange Rate Changes
0.01
+110.58%
-0.07
-608.53%
-0.01
+95.12%
-0.20
Beginning Cash Position
16.00
+47.98%
10.81
-68.82%
34.67
-32.91%
51.67
End Cash Position
25.01
+56.34%
16.00
+47.98%
10.81
-68.82%
34.67
Free Cash Flow
-10.27
-309.59%
4.90
+112.41%
-39.49
-117.54%
-18.15
Change In Interest Payable
0.57
+9.94%
0.52
0.00
—
Common Stock Issuance
20.93
+4514.44%
0.45
-95.15%
9.35
+666.91%
1.22
Issuance Of Capital Stock
20.93
+4514.44%
0.45
-95.15%
9.35
+666.91%
1.22
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category